| Name | Title | Contact Details |
|---|
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
Over 26 million Americans suffer from chronic kidney disease (CKD), including 1.5 million New Yorkers. Formed in 1972 as a philanthropic gift of Edwin and Rhoda Sperber, the Foundation provides services to patients, family members, the general public and clinical and academic professionals throughout the Northeast. The mission of the Northeast Kidney Foundation is to improve the quality of life of those affected by kidney disease and related conditions through early identification, intervention, prevention and support services; to promote organ donation; and to empower those we serve to be an effective voice for better healthcare at the local, state and federal levels.
Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Visit us at www.drugs.com.
PrimeSource Healthcare is a multi-specialty group of more than 150 board-certified Practitioners,Technicians and Patient Care professionals dedicated to providing the highest level of individualized, compassionate service that we call TotalCare. At
Unchained Labs is committed to building the first cool biologics tools company. One with products that`ll make a real difference in the research scientists do every day. One that UNleashes tools that help them characterize their biologics better. Founded in January 2015, we have raised $31M of venture capital and have purchased two product lines. First, we let loose the UNit, the world`s first and only multiplex protein stability platform. Next we landed another big win with ICD, the world`s first quantitative stability predictor. With these two products, we have established ourselves as the experts in protein stability